December 15th 2022
A biologic from Germany offers a new treatment option for a number of dermatologic conditions.
Voltaire-X Phase 3 Data for Chronic Plaque Psoriasis Support Interchangeability Application
April 26th 2021Voltaire-X study data shows that switching several times between Cyltezo and Humira results in similar pharmacokinetics, efficacy, immunogenicity, and safety in people with moderate to severe chronic plaque psoriasis.
IL-17, IL-23 Inhibitors May Outperform Older Biologics, Oral Therapies
January 21st 2021Several systemic therapies are currently available for the treatment of patients with moderate-to-severe psoriasis. Biologics changed the game for treatment. Continued study of and innovation in IL-17 and IL-23 inhibitors promise even better results, but clinicians need to understand each biologic in detail.
Safety profiles differentiate conventional therapies
November 11th 2020In a recent study, psoriasis drugs showed widely variable drug survival rates, owing to differences in safety, efficacy, patient satisfaction and other factors. However, concerns linger over potential to cause long-term cumulative organ toxicity.
Systemic psoriasis therapies not age-dependent
November 10th 2020Comorbidities, co-medication, organ impairment, functional deterioration and frailty make treatment plans challenging for older psoriasis patients. However, these patients should not be precluded but will require more extensive evaluation and assessment, according to a recent study.
Therapeutic, management considerations with biologics
July 24th 2020Studies offer further insight into risks associated with biologic therapy. One study suggests it’s not necessary to stop biologic therapy preoperatively to limit post-operative infections. Another systematic review does not rule out melanoma risk.
Biologic guidelines for psoriasis let providers choose
April 24th 2020When it comes to biologic drugs, the latest joint American Academy of Dermatology-National Psoriasis Foundation guidelines are less prescriptive than descriptive, offering a comprehensive discussion on the facts of each biologic to inform physicians’ selections.
Phase 3 results show risankizumab outperforms secukinumab
January 17th 2020Risankizumab (SKYRIZI, AbbVie), outperformed secukinumab (Cosentyx, Novartis) in a head-to-head phase 3 study comparing the two treatments in adult patients with moderate to severe plaque psoriasis, according to data released by the company Jan. 14.